{Reference Type}: Journal Article
{Title}: The 8-bromobaicalein alleviated chikungunya-induced musculoskeletal inflammation and reduced the viral load in healthy adult mice.
{Author}: Cao V;Loeanurit N;Hengphasatporn K;Hairani R;Wacharachaisurapol N;Prompila N;Wittayalertpanya S;Shigeta Y;Khotavivattana T;Chavasiri W;Boonyasuppayakorn S;
{Journal}: Emerg Microbes Infect
{Volume}: 12
{Issue}: 2
{Year}: 2023 Dec 16
{Factor}: 19.568
{DOI}: 10.1080/22221751.2023.2270074
{Abstract}: Chikungunya virus is a re-emerging arbovirus that has caused epidemic outbreaks in recent decades. Patients in older age groups with high viral load and severe immunologic response during acute infection are likely to develop chronic arthritis and severe joint pain. Currently, no antiviral drug is available. Previous studies suggested that a flavone derivative, 8-bromobaicalein, was a potential dengue and Zika replication inhibitor in a cell-based system targeting flaviviral polymerase. Here we characterized that 8-bromobaicalein inhibited chikungunya virus replication with EC50 of 0.49 ± 0.11 µM in Vero cells. The molecular target predicted at viral nsP1 methyltransferase using molecular binding and fragment molecular orbital calculation. Additionally, oral administration of 250 mg/kg twice daily treatment alleviated chikungunya-induced musculoskeletal inflammation and reduced viral load in healthy adult mice. Pharmacokinetic analysis indicated that the 250 mg/kg administration maintained the compound level above EC99.9 for 12 h. Therefore, 8-bromobaicalein should be a potential candidate for further development as a pan-arboviral drug.